Racing against Alnylam, Ionis posts positive PhIII ATTR efficacy numbers, but questions linger
One of the big rivalries in biotech right now is the race between Ionis $IONS and Alnylam $ALNY to field a new RNA therapy for hereditary TTR amyloidosis (hATTR) with polyneuropathy. And after Alnylam drew cheers for its top-line win, Ionis is rolling out a big peek at the bottom line.
Researchers posted a mean 19.73-point benefit for the neuropathy impairment score, its mNIS+7 co-primary endpoint after 15 months of treatment, saying that they could start tracking a statistically significant benefit at 8 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
